Monique Dail - Concepedia

Author

Monique Dail

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Lemmens, Ed, M Dail, Monique Dail

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center AbbVie (United States)University of California, San Francisco University of Colorado Denver University of Pennsylvania

About

Monique Dail is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	547
2	Cell Biology	6	6	415
3	Health Sciences	1	1	94
4	Natural Sciences	1	1	29
5	Cellular Physiology	1	1	77

Monique Dail

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor Mitchell Koolpe, Monique Dail, Elena B. Pasquale Journal of Biological Chemistry	2002	206
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia Naval Daver, Alexander E. Perl, Joseph Maly, Journal of Clinical Oncology	2022	179
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Journal of Clinical Oncology	2021	156
EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity Mitchell Koolpe, Rosemary Burgess, Monique Dail, Journal of Biological Chemistry	2005	141
Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Clinical Cancer Research	2022	137
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis, Haematologica Venetoclax MonotherapyHematological MalignancyVenetoclax CombinesLeukemic CellsMedicine	2020	134
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models Lina Han, Qi Zhang, Monique Dail, Haematologica	2019	111
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Blood	2024	108
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells Amit J. Sabnis, Laurene S. Cheung, Monique Dail, PLoS Biology	2009	101
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial Naval Daver, Monique Dail, Jacqueline S. Garcia, Blood Mixed-phenotype Acute LeukemiaPharmacotherapyTranslational PharmacologyMyeloid NeoplasiaHematological Malignancy	2022	94

Page 1